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Abstract
Background: With the recent decreasing cost of genome sequence data, there has been increasing interest in rare
variants and methods to detect their association to disease. We developed BioBin, a flexible collapsing method
inspired by biological knowledge that can be used to automate the binning of low frequency variants for
association testing. We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from
public databases, which contains resources such as: dbSNP and gene Entrez database information from the
National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database
(Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways,
Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid),
Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary
conserved regions (ECRs) from UCSC Genome Browser. The novelty of BioBin is access to comprehensive
knowledge-guided multi-level binning. For example, bin boundaries can be formed using genomic locations from:
functional regions, evolutionary conserved regions, genes, and/or pathways.
Methods: We tested BioBin using simulated data and 1000 Genomes Project low coverage data to test our
method with simulated causative variants and a pairwise comparison of rare variant (MAF < 0.03) burden
differences between Yoruba individuals (YRI) and individuals of European descent (CEU). Lastly, we analyzed the
NHLBI GO Exome Sequencing Project Kabuki dataset, a congenital disorder affecting multiple organs and often
intellectual disability, contrasted with Complete Genomics data as controls.
Results: The results from our simulation studies indicate type I error rate is controlled, however, power falls quickly
for small sample sizes using variants with modest effect sizes. Using BioBin, we were able to find simulated variants
in genes with less than 20 loci, but found the sensitivity to be much less in large bins. We also highlighted the
scale of population stratification between two 1000 Genomes Project data, CEU and YRI populations. Lastly, we
were able to apply BioBin to natural biological data from dbGaP and identify an interesting candidate gene for
further study.
Conclusions: We have established that BioBin will be a very practical and flexible tool to analyze sequence data
and potentially uncover novel associations between low frequency variants and complex disease.
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Background
The era of successful Genome Wide Association Studies
(GWAS) has contributed to over 1,596 published disease
variant associations for over 249 traits (http://www.gen-
ome.gov/gwastudies/, accessed July 2012) Published
GWAS results have increased the fields’ understanding
of heritable traits, highlighted novel disease associations
that were critical for further biochemical and pharma-
ceutical development, and advanced the perception and
understanding of genetic association and complexity of
common diseases [1,2]. However, large proportions of
variance in common complex diseases remain to be
explained [3]. In the last few years, sequence technology
has emerged as an successful approach to gain insight
into other genetic components contributing to disease,
including: low frequency or rare variants, mRNA tran-
script levels, etc.
In an effort to explain the additional heritability of
complex traits, many researchers are investigating the
effects of rare variants. The possible effects and complex
heritatibility of rare variants are largely unknown; how-
ever, it is commonly believed that rare variants have big-
ger effect sizes (compared to common variants identified
in GWAS) and can act alone, together with other rare
variants, or jointly with common variants [2]. There is
increasing evidence in published literature to support
the hypothesis that rare variants contribute to the her-
itiability of common, complex disease. Recently, rare
variants with moderate effect sizes have been associated
with obesity, autism, schizophrenia, hypertriglyceride-
mia, hearing loss, complex I deficiency, age-related
macular degeneration, kabuki syndrome, and type-1 dia-
betes [3-9]. The analysis of rare variants does not follow
GWAS protocols. The sparseness of rare variants requires
massive sample sizes for single-variant association tests.
Combining rare variants together substantially reduces the
sample size needed to find an association signal and also
accounts for genetic heterogeneity.
Collapsing and/or binning methods have been popular
because they reduce the degrees of freedom in the statisti-
cal test, are easily applied to case-control studies (not
limited to family transmission filtering), can utilize whole-
genome data, provide a means to enrich association signals
by combining rare variants which are often otherwise
undetectable, and allow for the investigation of collective
polygenic inheritance. In the past five years, many collap-
sing methods have been published [5,10-18]. Most of
these methods require significant bioinformatic pipeline
infrastructure developed by the individual users to apply a
method to their whole genome sequencing data, as they
have been tested using simulations on the order of candi-
date gene studies. The limited regional approach used by
most of these methods restricts novel discovery since a
particular set of genes or pathways must be selected for
analysis. In addition, considerable effort is necessary on
the part of the user if the hypothesis warrants unusual or
novel bin features. One method, VAAST has been designed
to complete analyses using whole-genome sequence data.
However, VAAST requires the user to generate and include
a feature file, which contains the explicit boundaries for
binning. This is trivial when the user wants to perform a
rare variant burden test in genes, but much more compli-
cated if the user needs to create pathway or regulatory
region feature files.
The conceptual notion of binning is a very good one,
but it is important to recognize four elements for
improved algorithm development:
1. Complexity of interactions (epistatic and in aggre-
gate) of rare and common variants
2. Potential non-independence between rare variants
and between bins
3. Importance and possible limitation of “user” feature
definition
4. Necessity of tool flexibility
Theoretically, there are many ways that variants can
interact or act in aggregate to affect a phenotype; at this
point, it is not known which will be true for the majority
of common, complex disease. Variants in the same region
can have opposing directions or effect, have no effect on
the phenotype at all, or be part of complex epistatic inter-
actions. Rare variants have been often considered to be
independent of one another in method development,
which is an assumption that is not necessarily true and
should be considered in the analysis to protect from type I
and type II errors [11,19]. Furthermore, bins, which con-
tain rare variants, are not independent, particularly since
the same variants can show up in multiple bins. Ideally,
the simulations and statistical analysis used to develop,
test, and support novel binning methods should reflect the
possibility that variants and bins are not independent.
Users generate a hypothesis prior to performing an
analysis, and in the case of collapsing algorithm; this
includes choosing how bin boundaries are determined.
Many current methods require additional input to inform
the method of these boundaries, which makes testing
multiple hypotheses or altering the hypothesis more diffi-
cult. Rather than requiring users to bin arbitrarily by
RefSeq gene boundaries or select candidate gene regions,
it is possible to bin within pathways, regions with known
regulatory elements, evolutionary conserved sequences,
and/or transcription factor binding sites. BioBin takes
advantage of the power of prior knowledge, and the
potential cumulative effect of rare variants in related bio-
logical networks.
Many current binning methods incorporate a fixed fea-
ture design focus for the statistical association test and
take for granted that variants are collapsed in the most
accurate and powerful way. The only exception is the
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application of functional prediction algorithms to filter
the variants before binning to bin variants with similar
directions of effect [11,19]. Adding a layer of specific fil-
tering for the binning process allows the user to investi-
gate biologically relevant collapsing boundaries that
ultimately increase likelihood of discovering meaningful
associations.
Our BioBin approach meets the criteria we have defined
for improved binning algorithm development. Instead of
focusing on a novel statistical test, we have concentrated
on biology-driven automated bin generation. Based on the
study hypothesis, the user selects binning features and Bio-
Bin creates appropriate feature level bins using information
from one or more of the databases in our integrated data-
base, call the Library of Knowledge Integration (LOKI).
BioBin to can create bins based on many features, includ-
ing: regulatory regions, evolutionary conserved regions,
genes, and/or pathways. In addition, users can utilize com-
plex binning, i.e. collapse only exons in pathways or per-
form regulatory and gene feature analyses simultaneously.
The innovation of BioBin and incorporation of prior biolo-
gical knowledge to automate bin generation allows the user
the opportunity to test unique hypotheses [2].
Below, we present the methodology of BioBin, the
underlying structure of LOKI that provides prior knowl-
edge to BioBin, as well the results of our testing of BioBin
with multiple datasets. We have tested BioBin using com-
pletely simulated rare-variant data, 1000 Genomes Pro-
ject data, and NHLBI GO Exome Sequencing Project
Kabuki dataset. Our tests show that BioBin is a flexible
binning algorithm, useful for biological knowledge direc-
ted binning of rare variant data.
Methods
General framework
The goal of a low-frequency variant collapsing analysis is
to compare the variant burden between two groups and
identify bins with a significant excess of variants in one
group compared to another. A bin analysis using BioBin
follows these steps: 1) the user determines the feature to
bin data (gene, pathway, etc), 2) BioBin executes the task
of bin generation, 3) the user applies an appropriate statis-
tical test to each bin. User-defined parameters and infor-
mation from LOKI determine the boundaries of the bin.
Users can adapt BioBin to their needs through the use of a
configuration file, which can be used to adjust features or
select certain database sources. When a variant is consid-
ered rare, which is defined as having a minor allele fre-
quency less than the user-defined threshold in either the
case or control group, it will contribute to the bin. By bin-
ning in this way, bins accumulate not only risk variants
which have higher frequency in cases than controls but
also potentially protective variants that have lower fre-
quency in cases than controls. Considering the rarity of
variants in the case and control groups separately reduces
the number of false positive bins and the association
between bin size and significance.
Additionally, the minor allele frequency threshold is
configurable. This threshold determines the allele fre-
quency limit under which variants are considered rare,
and therefore binned. For example, if the threshold is set
to 0.05, a locus with a minor allele frequency of 0.08
would not be included in a bin, but a locus with an allele
frequency of 0.049 would be included. BioBin defines the
minor allele at a given locus as the second most frequent
allele in the target group. For a biallelic locus, this is
always the rarer allele. For a polyallelic locus, the minor
allele frequency considered in the binning process is calcu-
lated from the second most frequent allele, and all non-
major alleles are binned identically. Common loci, defined
to be those loci with allele frequencies above the binning
threshold in both case and control groups, are not binned
and are not considered in the analysis. Table 1 shows an
example of major and minor allele frequency inclusion/
exclusion from a single bin.
BioBin software
BioBin is a C++ command line application that uses a
prebuilt LOKI database. Source distributions are avail-
able for Unix-based operating systems (Mac OSX and
Linux) and require minimal prerequisites to compile.
The source distribution includes tools that allow the
user to create and update the LOKI database by down-
loading the information directly from the respective
sources. The computational requirements for BioBin are
quite modest, a whole-genome analysis with 185 indivi-
duals took less than two hours. Since most current
sequence studies are whole-exome, this analysis repre-
sents the most taxing use case in the foreseeable future
The vast amount of data included in this particular ana-
lysis must be stored in memory, so the memory require-
ments can be high. For the same 185 individuals, BioBin
required approximately 12 GB of memory. We have
found that the primary driver of memory usage is the
number of rare variants in the analysis, but with cur-
rently available sequence datasets, BioBin can be run
quickly without access to expensive and specialized
computer hardware [2].
LOKI database
The utilization of prior biological knowledge is a power-
ful approach to inform collapsing feature boundaries.
BioBin relies on the LOKI database, implemented in
SQLite, for the integration of information from disparate
data sources. Currently, LOKI contains information
from sources such as: the National Center for Biotech-
nology (NCBI) dbSNP and gene Entrez database infor-
mation [20], Kyoto Encyclopedia of Genes and Genomes
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(KEGG) [21], Reactome [22], Gene Ontology (GO) [23],
Protein families database (Pfam) [24], NetPath - signal
transduction pathways [25], Molecular INTeraction
database (MINT) [26], Biological General Repository for
Interaction Datasets (BioGrid) [27], Pharmacogenomics
Knowledge Base (PharmGKB) [28], Open Regulatory
Annotation Database (ORegAnno) [29], and evolution-
ary conserved region information from UCSC Genome
Browser [30].
The creation of LOKI was a means to standardize inter-
face and terminology between different sources that each
contain potentially differing means of representing data.
The three central concepts utilized in LOKI are positions,
regions and groups. The term position is defined to be a
single location in the genome, and could represent data
such as rare variants (RVs), single nucleotide polymorph-
isms (SNPs), or single nucleotide variants (SNVs). A
region, as defined by LOKI, refers to a segment with a
defined start and stop position in the genome. Examples
of regions include genes, copy number variants (CNVs),
and evolutionary conserved regions (ECRs). LOKI uses the
term group to refer to a collection of regions that are con-
nected in some way. Each source, or database (such as
those listed above), may represent the collection of regions
in a different way, but LOKI standardizes all of the infor-
mation, which allows for uniform access and usage of the
prior biological knowledge [2].
SQLite is the relational database management software
chosen for the implementation of LOKI because it does
not require a dedicated database server. Before using Bio-
Bin, the user must run the provided installer scripts to
download and process the biological knowledge into a sin-
gle database file (~ 7 GB range). Due to the amount of
information downloaded from the various sources, a sys-
tem building a LOKI database should have at least 50 GB
of disk storage available. When used by BioBin, LOKI runs
locally and needs no connection to the Internet [2].
Binning approach
Due to ease of access and clearly defined database
schema, we chose NCBI dbSNP and NCBI Entrez Gene
as our authoritative sources of position and regional
information. Pathway/group bins were created using
sources in LOKI (detailed in software section). Inter-
region bins of a user-specified size were generated by
BioBin to catch variants that did not fit into the user-
defined features. Therefore, after BioBin feature selection,
inter-region bins were created. In other published collap-
sing methods, intergenic variants would typically not be
included in the analysis. Common binning strategies are
shown in Figure 1, which include gene, pathway, and
intergenic features, and the possibility of applying a func-
tional prediction filter.
Statistical testing
BioBin is a tool to create new feature sets that can be
examined in subsequent statistical analyses. BioBin output
provides information about the bins generated, summary
values, and a matrix of variant sums per individual for
each bin generated. Care should be taken with bin output
to choose a statistical test appropriate to the hypothesis
being tested, the question of interest, and the type of data
tested. The innovation of BioBin is its capacity to employ
feature selection using a knowledge base (see Figure 2).
The resulting RV bins can be used in a variety of statistical
analyses; there are explicit situations that require the use
of regression analysis (logistic, linear, or polytomous),
Fisher’s exact test, or permutation of unique statistical
test, etc. In order to appeal to the broadest user base, no
specific statistical test is implemented into BioBin. In com-
parison, other collapsing methods do not generate bins
based on biological knowledge; instead, they focus on the
association test and results after bin generation [2]. The
results we present below were calculated using a Wilcoxon
2-sample rank sum test implemented in the R statistical
package [31].
Simulation strategy
To test BioBin, we simulated genetic data using SimRare
[32]. SimRare is a GUI interface simulation program built
on top of a forward time simulator, simuPOP [33]. simu-
POP simulates the introduction and evolution of rare
variants and allows complex fitness and selection model-
ing [http://simupop.sourceforge.net, https://code.google.
com/p/simrare/]. There are a few reasons SimRare is pre-
ferable to simuPOP for the end user: it is computationally
efficient, time efficient, and reduces the number of link-
ing scripts needed to create a many replicates of simu-
lated data.
We used an additive multi-locus selection model with
a selection distribution described by Kryukov [34]. The
mutation rate was set at of 1.8 × 10-8 per nucleotide per
Table 1 Minor allele frequency threshold example
Major Allele (AF) Minor Allele(s) (AF) MAF Variants Binned (Threshold = 0.05)
C: 0.97 T: 0.03 0.03 T
T: 0.80 A: 0.16, G: 0.04 0.16
G: 0.95 C: 0.03, T: 0.02 0.03 C, T
Binning of major and minor allelle frequencies in sequence data given a minor allele frequency threshold of 0.05.
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generation. The population sizes were Ne = 8100, 8100,
7900, and 900000 with 5000 generations, 10 generations,
and 370 generations respectively. A fixed 5kb region
was simulated using 250 replicates of the same evolution
parameters. In this instance the term replicate is a
realization of the forward-time simulation using the
given input parameters, and each replicate is not identi-
cal since evolution cannot be exactly repeated due to
randomness. However, more replicates slightly increase
the diversity of the final simulated data.
Figure 1 Example binning strategies. Binning example using four genes, two pathways, and functional prediction.
Figure 2 Pipeline for BioBin analysis. Pipeline for BioBin analysis. Blue squares correspond to data, green hexagons correspond to
bioinformatic or statistical method applications.
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Assessing type I error
To evaluate type I error, we generated a sample data set
with the following parameters: 1.0 odds ratio for protec-
tive mutations, 1.0 odds ratio for detrimental mutations,
and an additive mode of inheritance. We did not incor-
porate missingness or unphenotyped individuals. The
type I error was computed as the percentage of the
4,000 replicates with a p-value <= 0.05. A type I error
rate above 5% would indicate a high likelihood of false
positives and a type I error rate lower than 5% would
indicate a conservative test.
Power
To evaluate power, we generated a sample data set with
the following parameters: 0.9 odds ratio for protective
mutations, 2.5 odds ratio for detrimental mutations, and
an additive mode of inheritance. Again, we did not
incorporate missingness or unphenotyped individuals.
The power was computed as the percentage of the 4,000
replicates with a p-value <= 0.05.
1000 Genomes Project data comparison
Simulation studies are useful for many reasons but can-
not account for 100% of the heterogeneity in natural
data. Low frequency variants are often specific to conti-
nental populations or even to individual populations [35].
1000 Genomes Project data was used to test BioBin, and
contrast results with our completely simulated rare-
variant data. The 1000 Genomes Project was started in
2008 with the aim to deliver deep characterization of var-
iation in the human genome. As of October 2011, the
sequencing project included sequence data for 1094 indi-
viduals, with the intent to sequence 2,500 individuals by
the time of the project’s completion. The project reports
capture 95% of all variation with frequencies greater than
1% [36]. We utilized the 1000 Genomes Project data in
two ways, 1) adding resequenced variants to a study of
cases and controls from 1000 Genomes data of the same
ancestral population to determine BioBin’s ability to
resolve a large simulated signal in the midst of various
amounts of background variation 2) pairwise rare variant
burden comparison using 1000 Genomes Project data
between two ancestral populations to expose known pat-
terns of population stratification.
1) Adding resequenced variants
First, we tested BioBin by adding a simulated variant
with 100% penetrance to two genes on chromosome 7
in a case-control sample composed of individuals of
European descent (CEU). Individuals were randomly
assigned case/control status from the 87 unrelated CEU
samples. As the added variant had 100% penetrance,
each case was assigned as a heterozygote and each con-
trol was homozygous referent for the simulated variant.
An additive genetic model was used to detect rare var-
iant burden under three minor allele frequency bin
threshold conditions (0.02, 0.05, 0.10). Testing the bins
under different allele frequency threshold conditions
affords an easy way to test the same bins with more or
less variants, which can provide some information about
the sensitivity of this binning method.
We added our simulated variant to the gene GLI3 (GLI
family zinc finger 3), a large gene associated with poly-
dactyly syndrome [OMIM 174200]. This gene has
between 262 and 602 variant loci indicating a very poly-
morphic gene in the CEU genome (including the simu-
lated variant). The addition of one simulated variant loci
added a total of 43 variants (each case is heterozygous
and only contributes one variant to bin). In a second test,
we randomized the case/control status again and added a
simulated variant to the gene CAV2 (protein cavelolin-2,
induced during adipocyte differentiation), with between
9-20 variant loci (including the simulated variant). BioBin
was then used for a rare variant burden test across the
chromosome 7 genomic region to see if either the GLI3
or CAV2 signal could be identified as significantly asso-
ciated using a Wilcoxon Rank Sum test.
2) Pairwise comparison in YRI and CEU
Second, we compared two populations, YRI and CEU,
from 1000 Genomes Project to highlight rare variant bur-
den differences. Rare variants found at different frequen-
cies among ethnic-specific populations and sequence data
is available through 1000 Genomes Project for a large
number of individuals (October 2011 release ftp://ftp-
trace.ncbi.nih.gov/1000genomes/ftp/release/20110521/).
This analysis included 87 CEU samples and 88 YRI sam-
ples. We used BioBin to conduct a pairwise comparison of
rare variant burden differences (MAF < 0.03) based on
known gene regions (start and stop positions form bin
boundaries), intergenic regions (intergenic variants caught
by 50kb bins) and known pathways (gene bins in the same
pathway are collapsed into one pathway bin).
NHLBI Kabuki dataset test
We utilized the NHLBI Kabuki dataset available on dbGaP
(http://www.ncbi.nlm.nih.gov/gap/) April 2012. According
to the authors of the original study, ten unrelated indivi-
duals with Kabuki syndrome were sequenced: 7 of Eur-
opean ancestry, 2 of Hispanic ancestry, and one of mixed
European and Haitian ancestry. Shotgun fragment libraries
were hybridized to custom microarrays, and then enriched
using massively parallel sequencing [8]. The raw fastq files
were downloaded from dbGaP and processed using stan-
dard exome algorithms: bwa, samtools, picard, GATK, and
bedtools. We used publically available Complete Geno-
mics whole-genomes sequences for 54 unrelated indivi-
duals from 11 populations as the control group for this
experiment [37]. We used a MAF binning threshold of
0.05 and filtered out variants present in 1000 Genomes
Project data to collapse rare variants based on known gene
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regions (start and stop positions form bin boundaries) and
known pathways (gene bins in the same pathway are col-
lapsed into one pathway bin).
Although a sample of ten individuals across multiple
ancestries do not provide reasonable power to achieve sta-
tistical significance for identified rare variant trends, it was
still useful for showing how BioBin can be used to priori-
tize bins based on rare variant burden differences.
Results
Simulation results
Using SimRare, a 5kb genomic region was simulated with
an average of 968 rare variants as described in the meth-
ods section for four sample sizes (N = 2000, 1000, 500,
250). Case/control status was evenly and randomly
assigned in each of the 4000 replicates. The type I error
rate was calculated as the number of replicates with p-
value <= 0.05 divided by the total number of replicates.
Shown in Table 2, the type I error tests indicate that the
Wilcoxon 2-sample rank sum test was marginally anticon-
servative. This conveys that using a Wilcoxon 2-sample
rank sum test controls the false-positive rate in BioBin.
Similarly, power was assessed using a 0.9 odds ratio for
protective mutations and 2.5 odds ratio for detrimental
mutations with an additive mode of inheritance. We calcu-
lated the power of the Wilcoxon test as the proportion of
the 4,000 replicates at each sample size with a p-value <=
0.05. The power dropped to less than 80% in sample sizes
less than 1000.
1000 Genomes comparisons
Statistical analysis using bin output can be complicated
considering dependent bin and variant architecture, var-
iance in bin size, and complex genetic models. We used
1000 Genomes CEU data to evaluate if a) BioBin could
detect bins containing a 100% penetrant simulated variant
b) determine if bin size (number of variants in a bin) could
affect the strength of a simulated association signal by
seeding the variant into two genes with very different
numbers of non-simulated variants, testing different
minor allele frequency binning thresholds to see how the
p-value changes with respect to small changes in the num-
ber of variants collapsed in the bin. BioBin can detect bins
containing the penetrant simulated variant, but this is
affected greatly by the number of other variants in a given
bin. The results are shown in Table 3: the MAF threshold
corresponds to the binning threshold, the number of loci
indicates the number of physical positions in the bin
region that contribute at least one variant, the number of
bins corresponds to the number of bins generated on
chromosome 7. Table 3 also shows the number of signifi-
cant bins for each analysis and the rank of the gene of
interest. For example, as shown in Table 3, the signal was
completely mitigated by noise in the GLI3 bins. GLI3 has a
large number of variants in addition to the simulated var-
iant. While the statistical test did not identify GLI3, there
were also no false positives. There were no significant bins
in any of the three GLI3 analyses. The CAV2 bin was sta-
tistically significant after Bonferroni correction when the
minor allele frequency threshold was less than or equal to
0.05, a gene with a very low number of additional non-
simulated variants.
These two simulated variants scenarios were tested
separately in BioBin. As a result, the phenotypes were
randomly assigned, thus allowing for different bins to be
generated based on which and how many variants met
the MAF binning threshold criteria.
We also tested BioBin using whole-genome popula-
tion data from 1000 Genomes Project. Because of
known population stratification between CEU and YRI,
this is a reasonable rare variant burden test. using
whole-genome data. For 87 CEU and 88 YRI indivi-
duals, there are approximately 11 million variants (rare
and common) in the CEU sample and approximately
18 million variants in the YRI sample, an indication of
similarity/dissimilarity to the reference genome In
addition to having more variants, it is also clear that of
these variants, there is a larger proportion of low fre-
quency variants in the YRI sample. Figure 3 shows the
whole-genome minor allele frequency density distribu-
tion of CEU and YRI populations.
Using a MAF binning threshold of 0.03, we binned
genes, pathways, and intergenic regions. The results of this
test are shown in Table 4, where “Feature Type” defines
the bin boundaries, “Bins” corresponds to the number of
bins generated by prior knowledge in BioBin given the fea-
ture type, “Sig. Bins” is the number of bins (out of the total
in that feature type) that were statistically significant after
a Bonferroni multiple testing correction, and “% Sig.” is
the proportion of significant bins divided by the total
number of bins. However, because of evolutionary pres-
sures we expected less diversity in gene regions than inter-
genic regions because it is likely coding regions have
evolved lower mutation rates than noncoding regions.
Pathways show the highest proportion of significant bins,
however, significantly different but common gene regions
are likely influencing the pathway analysis. In all three fea-
tures, there is a surprisingly high proportion of significant
bins.
Table 2 Simulation results





Rare variant simulation using SimRare to assess power and type I error rate.
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NHLBI Kabuki dataset
We used BioBin to collapse the whole-exome data for
10 Kabuki individuals with 54 individuals from Com-
plete Genomics whole-genome data. The 10 Kabuki
cases were sequenced using an exome-capture kit for an
average coverage of 40x on the mappable, targeted
exome [8]. The 54 Complete Genomics samples were
sequenced with an average genome-wide coverage of
80X [37]. In the original Kabuki analysis, Ng et al. used
a filtering method to identify MLL2 as a possible causa-
tive gene for Kabuki syndrome. In this analysis, in order
to compare the cases and controls, we filtered both
datasets by exome boundaries (available from UCSC)
and filtered out variants present in the 1000 Genomes
Project Phase I data. BioBin produced the MLL2 gene
bin with 125 total variant loci (184 total variants) at a
minor allele frequency threshold of 0.05, but was not
significant (p-value = 0.4718).
Discussion
Simulation results
Shown in Table 2, the Wilcoxon 2-sample rank sum test is
slightly anticonservative but independent of sample size
and is not of much concern. Further exploration should
be performed to evaluate the relationship between rare
variant allele frequency distribution and type I error, to
calculate the type I error using a variety of sample popula-
tion sizes, and to examine if the number of variants in a
bin consistently inflate the false positive rate. The power is
greater than 90% at sample sizes of 1000 and 2000 indivi-
duals. The power drops to 75% at a sample size of 500 and
50% at a sample size of 250. While the power drops dra-
matically with decreasing sample size, it is important to
note that power to detect associations relies heavily on the
effect size of the variants [38]. In the case of population
stratification, the penetrance is quite high and the effect
size is related to the allele frequency difference between
Table 3 Analysis with simulated variants in GLI3 and CAV2
Gene MAF Thres Location Size Loci # Bins # Sig. Bins Overall Rank Unadj. P-val* Adj. P-val
GLI3 0.02 7:42000547-42276618 276kb 262 1539 0 1377 0.9828 1
GLI3 0.05 431 1692 0 1288 0.7723 1
GLI3 0.10 602 1730 0 1273 0.7404 1
CAV2 0.02 7:116139654-116148595 109kb 9 1612 1 1 1.731e-17 2.791e-14
CAV2 0.05 11 1701 1 1 2.338e-14 3.976e-1
CAV2 0.10 20 1735 0 3 0.0005869 1
A simulated variant was added to two genes, GLI3 and CAV2. The genes were used to test signal mitigation in the presence of a large versus small number of
variants in the bin. The adjusted p-values were calculated using a Bonferroni correction to account for the total number of bins generated.
Figure 3 Minor allele frequency distribution for CEU and YRI. Minor allele frequency distribution for CEU (red) and YRI (blue) populations.
The African population has a higher density of low frequency variants.
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the two populations, which is often several fold higher
than the 2.5 odds ratio of the simulated dataset.
1000 Genomes Project comparison
1000 Genomes Project has provided a unique opportunity
to evaluate bins on natural data. In the first test, BioBin
was used to identify bin containing simulated variants
with known association to a simulated phenotype. These
steps were taken for two genes with very different rare var-
iant backgrounds. For example, using a minor allele fre-
quency-binning threshold of 0.05, GLI3 had 431 variant
loci with 1099 total variants in the CEU group. At the
same binning threshold, CAV2 had 11 variant loci with 57
variants in the CEU group. We expect causative rare var-
iants to be highly penetrant, but clearly the power of Bio-
Bin to detect a signal with a large main effect is greatly
affected by the number of other variants in the bin. Using
GLI3 as an example, when there were greater than 300
variants in the bin, the true signal was mitigated by the
noise. However, when there were less than 20 variants in
the bin, a single variant with a large main effect was easily
detected. Optimistically, in natural data each case has one
or more rare-variants in addition to the natural back-
ground variation (which would also be present in con-
trols). The number of variants in the background variation
is deterministic of detecting a signal; this exemplifies the
importance of maintaining bins of a reasonable size. How-
ever, if there are more causative variants acting in concert
with a relatively high penetrance, this signal will be more
robust. It also emphasizes the impact of flexible binning.
The ideal bin will have as many rare variants with the
same direction of effect and very few neutral variants. This
has been shown to improve power in other methods [11].
To do this, other available methods would require some
bioinformatic filtering in addition to the collapsing
method. For BioBin, this is a matter of choosing more
explicit binning instructions. For example, split pathway
“A” bin into pathway “A” exons and pathway “A” introns.
Another way to reduce the number of variants in a bin is
to apply functional predictions. One could use Polyphen
output for variants in the input dataset, and BioBin with
generate pathway “A” risk variants and pathway “A” non-
risk variants. One potential disadvantage of Polyphen or
any other prediction algorithm is that only variants with
prediction scores would be included in the bins, while all
other would be excluded from the analysis. To accommo-
date the needs of the user, BioBin accepts a generic form
of prediction output, which makes it possible to use
almost any available tool but also accommodates novel
functional prediction algorithms.
In the subsequent test using 1000 Genomes Project
whole-genome data, we used BioBin to identify features
with significant differences in rare variant burden. A
similar method was used by Madsen and Browning and
Moore et. al [2,12]. A population-genetics approach
implies case/control status by ancestry identification, but
also retains natural qualities of data. Madsen et al. used
five 100kb regions from Encode III data sequenced in dif-
ferent populations. To mimic disease resequencing, they
grouped exonic rare variants by each region and com-
pared between African Yoruba individuals (YRI) and
European descent individuals (CEU) [12]. Similarly, we
compared three feature types between two ancestral
populations from 1000 Genomes Project. This is interest-
ing because it provides another approach to test BioBin,
but also because population stratification is a known
issue in genomic studies and could be useful knowledge
for more traditional case/control analyses in sequence
data. BioBin discovered features with rare variant burden
differences between CEU and YRI populations. For each
feature tested (genes, intergenic, and pathways), the
majority of bins had statistically significant differences
(adjusted using Bonferroni multiple testing correction) in
rare variant burden. We investigated allele frequencies in
the binned loci in CEU and YRI individuals, over 65% of
the variant loci were fixed in the CEU individuals. This is
not surprising since it is well known that individuals of
African descent have more variation than individuals of
other ancestral groups when compared to the reference
genome. The difference in rare variation is driving the
high percentages seen in Table 4.
It is also interesting that the rate of variation between
CEU and YRI is not consistent across each feature tested.
Gene bins had fewer significant rare variant differences
than intergenic and pathway bins. Perhaps we see overall
less variability in these regions because mutations are less
tolerated. It has been suggested that genes undergo adap-
tive evolution, thus regions with potential for highly dele-
terious mutations such as genes, evolve lower mutation
rates [39,40]. This stratification is an interesting result for
BioBin but also indicates a need to further investigate the
possible effect of feature specific rare variant stratification
in sequencing studies.
NHLBI Kabuki dataset
Ng et al. filtered out 1000 Genome variants and other
non-causative variants from previous Kabuki studies.
They also considered only nonsynonymous variants with
Table 4 Feature analyses applied to CEU-YRI comparison
Feature Type Bins Sig. Bins % Sig
Genes 31519 17436 55.3190
Intergenic 40362 28447 70.4797
Pathways 118221 99445 84.1179
Four features were tested on the CEU-YRI population comparison using BioBin
to investigate differences in rare variant burden. The table shows the total
number of bins, number of signficant bins (after Bonferroni correction), and
the percent of significant bins
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predicted function. However, ten individuals with whole-
exome data is not a large enough case sample size for
sufficient power in a Wilcoxon 2-sample rank sum test.
The uneven sample size and different sequencing
approach for cases and controls is major limitation. To
compare the cases and controls, we filtered both datasets
by exome boundaries (available from UCSC). Because of
the sample size limitation, reducing potentially neutral
variants that contribute noise was advantageous. We
removed any variants that were present in the 1000 Gen-
omes Project Phase 1 release (14 populations, 1094 indi-
viduals) [36]. Then we used a minor allele frequency-
binning threshold of 0.05 to bin gene and pathway
features.
We have not used the same exact filters and have very
low power for a case-control study, which together, likely
explain why MLL2 was not more significant in this analy-
sis. In addition, population stratification exists in the cases
and controls and was not accounted for in this analysis.
Lastly, MLL2 has 54 exons and quite a bit of neutral varia-
tion. As shown in Table 3, larger bins with increased back-
ground variation make causative signals harder to detect.
While replication for MLL2 was absent, one of the top
pathways included EMG1, previously associated with
Bowen- Conradi syndrome (pathway adjusted p-value <
0.001, gene adjusted p-value < 0.001). Bowen-Conradi syn-
drome has a much more severe phenotype, but shares two
disease characterizations with Kabuki: impaired growth
and mental retardation [41]. Given the described analysis,
BioBin results should be utilized as a prioritization
method; thus, it would require a much larger sample size
to investigate the robustness of the EMG1 association. To
improve this analysis, one could potentially use a principle
components analysis to adjust for the variant confounding
between the two groups in a regression analysis or per-
form a permutation test to help adjust for unknown con-
founding. A better test data set would include at least 150-
200 individuals that were sequenced on the same platform.
Overall, BioBin can be used as a filtering mechanism to
group data and evaluate rare variant burdens between two
groups, but requires a more substantial sample size to gain
power to detect significance.
Conclusions
To explain more phenotypic variation in common com-
plex disease, it is imperative to consider genetic varia-
tion beyond common single nucleotide polymorphisms.
Rare variant analyses are appealing since effect sizes are
likely larger [1]. However, to improve power, one must
consider groups of rare variants with similar properties.
BioBin is a novel collapsing method that uses allele fre-
quency data and biological information to bin rare var-
iants. There are many advantages of using a biologically
informed method [2]:
1. Capability for whole-genome and whole-exome
analyses
2. Practical method for data reduction in sequence
data analysis
3. Utilizes domain knowledge to prioritize results for
association testing
4. Accurate binning increases the statistical power to
detect associations
5. Gene based output can formatted to identify GxG,
GxE, and gene-drug interactions
6. Can be combined with common variant methods
7. Provides framework to integrate numerous types of
complex data sets
BioBin is unique because it relies on LOKI and does
not include any statistical method. The user can easily
test complicated and interesting hypotheses on many
features. LOKI provides access to integrated biological
knowledge (pathways, groups, interactions, ECRs, regu-
latory regions, etc.), which is valuable to researchers that
do not want to spend considerable effort to combine
this knowledge manually. Additionally, the output of
BioBin can be subsequently analyzed using the associa-
tion tests most appropriate for their data analysis. For
any given bin, many statistical tests from other pub-
lished collapsing methods can be applied to BioBin
output.
Using a Wilcoxon 2-sample rank sum test, we have
shown that the type I error rate is controlled, but that
substantial (>500) sample sizes are needed to have
greater than 80% power to detect rare variants with
modest effect sizes. With BioBin, we were able to find
simulated variants in genes with less than 20 loci, but
found the sensitivity to be much less in large bins. This
will be investigated further so that we can better control
bin size for gene regions or groups, such as pathways.
From the population comparison analysis, we learned
more about the large degree of population stratification
between CEU and YRI populations from 1000 Genomes
data. Lastly, we were able to apply BioBin to natural bio-
logical data from dbGaP.
With the rapid increase in available sequence data and
available biological knowledge, we believe that BioBin
will continue to be a useful analysis tool. The ability to
quickly form and test unique, interesting, and biologi-
cally relevant hypotheses using aggregated low frequency
variation will aide scientists in revealing hidden herit-
ability for common complex disease. Software for BioBin
is publicly available for download at https://ritchielab.
psu.edu/ritchielab/software.
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